Team In Training raises funds in support of The Leukemia & Lymphoma Society (LLS).
The mission of LLS is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.
LLS exists to find cures and ensure access to treatments for blood cancer patients. We are the voice for all blood cancer patients and we work to ensure access to treatments for all blood cancer patients.
As there are no means of preventing or early screening for most blood cancers, the LLS research agenda is focused on finding cures. LLS drives research in areas of unmet medical need, and helps to bridge the gap between academic discovery and drug development. LLS identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies.
Learn more about our Research Investment.
LLS is the leading source of free, highly specialized blood cancer information, education and support for patients, survivors, families and healthcare professionals. We touch patients in their communities through our chapters across the U.S. and Canada. We advocate for blood cancer survivors and their families, helping patients navigate their cancer treatments and ensuring they have access to quality, affordable and coordinated care.
Policy and Advocacy
LLS recognizes that finding cures is not enough; we need to ensure that patients have access to the treatments, services and providers they need to live longer, better, healthier lives. LLS is dedicated to removing barriers to care. By providing our network of advocates a powerful voice, the Policy and Advocacy Team drives policies that accelerate the development and approval of innovative treatments and ensure that patients have sustainable access to quality, affordable coordinated care. Our team is committed to ensuring that patients have access to adequate network of providers and services and are protected from high out-of-pocket costs that limit access to life-saving treatments.